Groundbreaking CRISPR Treatment for Sickle-Cell Disease Receives UK Approval
Regulators in the United Kingdom have given the green light to Casgevy, the first treatment developed through CRISPR, a groundbreaking gene-editing technique. Manufactured by Boston-based Vertex Pharmaceuticals and Switzerland-based CRISPR Therapeutics, Casgevy aims to cure sickle-cell disease and its related condition, beta-thalassemia. Around 2,000 patients in the UK suffering from sickle-cell disease or beta thalassemia […]
Read More